Corvus eczema drug improves key symptoms for 75% in early trial

Corvus Pharmaceuticals (NASDAQ: CRVS) reported positive Phase 1 cohort 4 results for oral soquelitinib in moderate-to-severe atopic dermatitis. At Day 56 (n=12 soquelitinib, n=10 evaluable placebo) soquelitinib achieved EASI 75 in 75%, EASI 90 in 25% and IGA 0/1 in 33%, with mean EASI reduction of 72% vs 40% placebo and a statistically significant separation (p=0.035). Safety showed adverse events in 41.7% of treated patients vs 50% placebo; all events were Grade 1-2 with no serious adverse events. Biomarkers showed reductions in IL-4, IL-5, IL-17 and increased Treg cells. Corvus plans a ~200-patient Phase 2 trial in Q1 2026 with multiple dose arms and 12-week treatment.

https://www.stocktitan.net/news/CRVS/corvus-pharmaceuticals-announces-positive-data-from-cohort-4-jkipvwfkpbko.html